[HTML][HTML] Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients
VG Hall, VH Ferreira, M Ierullo, T Ku, T Marinelli… - American Journal of …, 2021 - Elsevier
Solid organ transplant recipients are at high risk of severe disease from COVID-19. We
assessed the immunogenicity of mRNA-1273 vaccine using a combination of antibody …
assessed the immunogenicity of mRNA-1273 vaccine using a combination of antibody …
[HTML][HTML] Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients
VG Hall, VH Ferreira, M Ierullo, T Ku… - American Journal of …, 2021 - ncbi.nlm.nih.gov
Solid organ transplant recipients are at high risk of severe disease from COVID-19. We
assessed the immunogenicity of mRNA-1273 vaccine using a combination of antibody …
assessed the immunogenicity of mRNA-1273 vaccine using a combination of antibody …
Humoral and cellular immune response and safety of two‐dose SARS‐CoV‐2 mRNA‐1273 vaccine in solid organ transplant recipients
VG Hall, VH Ferreira, M Ierullo, T Ku… - American Journal of …, 2021 - Wiley Online Library
Solid organ transplant recipients are at high risk of severe disease from COVID‐19. We
assessed the immunogenicity of mRNA‐1273 vaccine using a combination of antibody …
assessed the immunogenicity of mRNA‐1273 vaccine using a combination of antibody …
[PDF][PDF] Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients
VG Hall, VH Ferreira, M Ierullo, T Ku, T Marinelli… - 2021 - researchgate.net
Solid organ transplant (SOT) recipients are at high risk for complications from infection with
the coronavirus disease 2019 (COVID-19). 1, 2 The use of exogenous immunosuppression …
the coronavirus disease 2019 (COVID-19). 1, 2 The use of exogenous immunosuppression …
Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients.
VG Hall, VH Ferreira, M Ierullo, T Ku… - American Journal of …, 2021 - europepmc.org
Solid organ transplant recipients are at high risk of severe disease from COVID‐19. We
assessed the immunogenicity of mRNA‐1273 vaccine using a combination of antibody …
assessed the immunogenicity of mRNA‐1273 vaccine using a combination of antibody …
Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients
VG Hall, VH Ferreira, M Ierullo, T Ku… - … : official journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Solid organ transplant recipients are at high risk of severe disease from COVID-19. We
assessed the immunogenicity of mRNA-1273 vaccine using a combination of antibody …
assessed the immunogenicity of mRNA-1273 vaccine using a combination of antibody …
[引用][C] Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients
VG Hall, VH Ferreira, M Ierullo, T Ku… - American Journal of …, 2021 - cir.nii.ac.jp
Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273
vaccine in solid organ transplant recipients | CiNii Research CiNii 国立情報学研究所 学術情報 …
vaccine in solid organ transplant recipients | CiNii Research CiNii 国立情報学研究所 学術情報 …
[HTML][HTML] Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients
VG Hall, VH Ferreira, M Ierullo, T Ku… - American Journal of …, 2021 - amjtransplant.org
Solid organ transplant recipients are at high risk of severe disease from COVID-19. We
assessed the immunogenicity of mRNA-1273 vaccine using a combination of antibody …
assessed the immunogenicity of mRNA-1273 vaccine using a combination of antibody …
Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients.
VG Hall, VH Ferreira, M Ierullo, T Ku, T Marinelli… - 2021 - cabidigitallibrary.org
Solid organ transplant recipients are at high risk of severe disease from COVID-19. We
assessed the immunogenicity of mRNA-1273 vaccine using a combination of antibody …
assessed the immunogenicity of mRNA-1273 vaccine using a combination of antibody …